Matthew Matasar, MD

home / authors / matthew-matasar-md

Matthew Matasar, MD, is the chief of blood disorders at Rutgers Cancer Institute.

Articles

EHA 2025 Congress Recap | Image Credit: Venngage

June 16th 2025

Global Hematology Experts Reflect on Key Takeaways From the EHA 2025 Congress

Brooke McCormick Marina Kremyanskaya, MD, PhD Lorna Warwick Xavier Leleu, MD, PhD Ashley Yocum, PhD Matthew Matasar, MD Adela Perolla, MD, PhD

At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.

June 14th 2025

Phase 3 POLARGO Trial Shows Survival Benefit of Polatuzumab-Based Regimen in R/R DLBCL: Matthew Matasar, MD

Brooke McCormick Matthew Matasar, MD

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to Matthew Matasar, MD, of Rutgers Cancer institute.